Vancouver, British Columbia – (April 3, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the abstract submitted to the American Society of Clinical Oncology (ASCO) under Dr. Andrew Maksymiuk was accepted for online publication. The abstract was titled “Follow-up evaluation of outliers with elevated spermine-spermidine acetyltransferase-1 activity”.



Rashid Ahmed, President and CEO, says, “This is an important milestone for BioMark and we are delighted with the scientific and clinical progress our team has made over the past few months. This year, ASCO received more than 6,200 abstracts, which were reviewed by their Scientific Program Committee and ASCO Leadership.” The 2019 ASCO Annual Meeting will be take place May 31 – June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois.  The majority of abstracts, including our abstract, will be released by ASCO on May 15, 2019, at 5:00 PM EDT on


About ASCO

Founded in 1964, the American Society of Clinical Oncology is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. ASCO has over 45,000 members globally. For the 2019 ASCO annual meeting the focus will be on a unique global exchange of information on how to drive progress and expand the reach of quality care for all patients. Learn More about ASCO at

Press Release – BioMark’s Abstract Accepted For ASCO 2019 Online Publication

Share this post:

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
FSE: 20B

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.